Oaktree Acquisition Corp. III Life Sciences OACC

Oaktree Acquisition Corp. III Life Sciences is a newly organized blank check company incorporated on June 28 2024 as a Cayman Islands exempted company. It was formed for the sole purpose of effecting a merger share exchange asset acquisition share purchase reorganization or similar business combination with one or more businesses. The company’s sponsor is an affiliate of Oaktree a global investment management firm with extensive experience in healthcare and life sciences investments. The management team includes professionals who have previously led other Oaktree sponsored SPACs that successfully combined with Hims & Hers Health Inc and Alvotech. The company intends to concentrate its search on healthcare or healthcare related industries specifically biopharmaceutical medical devices diagnostics and specialized healthcare services. Its geographic focus is limited to North America the United Kingdom and Western Europe where the sponsor’s investment team has deep relationships. The company has not yet identified any specific target for a business combination and remains in the search phase following its initial public offering.

The company has generated no operating revenues to date and does not expect to generate operating revenues until it consummates its initial business combination. As a special purpose acquisition company its current activities are limited to organizational efforts the initial public offering and the search for a suitable target. The proceeds from its IPO are held in a trust account and are intended to be used as consideration for a future business combination. Until a combination is completed the company relies on the trust funds to cover operating expenses such as legal accounting and administrative costs. It does not sell any products or services to external customers and therefore reports zero revenue in its financial statements. Any future revenue will be derived from the completion of a business combination and the subsequent operations of the acquired entity.

Oaktree Acquisition Corp. III Life Sciences positions itself as a healthcare focused special purpose acquisition company backed by Oaktree a global investment manager with over two hundred twenty three billion dollars in assets under management as of December 31 2025. Oaktree’s life sciences platform has committed approximately six point two billion dollars across fifty four investments with no realized losses since its inception in 2013. This investment history provides the company with deep sector knowledge and a proven ability to source and evaluate healthcare targets. The company benefits from Oaktree’s extensive network of institutional investors banks brokers and other financial intermediaries that can generate deal flow. In the healthcare SPAC arena several competitors exist but few combine the sponsor’s scale with a dedicated life sciences team that has avoided losses in its private lending activities. The management team’s prior experience with Oaktree Acquisition Corp and Oaktree Acquisition Corp II gives it insight into the SPAC process and post combination value creation. These factors are intended to improve the likelihood of identifying an attractive target negotiating favorable terms and completing a transaction that supports long term shareholder value.

As a pre revenue blank check company Oaktree Acquisition Corp. III Life Sciences does not currently serve customers in the traditional sense. Its future customers will be healthcare companies that seek to access the public markets through a merger or similar transaction with the SPAC. These target companies operate in sectors such as biopharmaceutical medical devices diagnostics and specialized healthcare services. The company’s geographic focus remains North America the United Kingdom and Western Europe reflecting the sponsor’s investment expertise and network. Potential targets include firms that have developed commercial stage products or services and possess attractive cash flow profiles or unit economics. The SPAC does not disclose the names of any prospective targets because it has not yet selected a business combination partner. Accordingly the customer base is described by the types of healthcare businesses it intends to combine with rather than by a list of specific entities.